Event - 22/10/2024 2nd Biointelligence Congress in Stuttgart Stuttgart (Germany), Kongress/Symposium https://www.gesundheitsindustrie-bw.de/en/event/2nd-biointelligence-congress-stuttgart
Press release - 18/01/2024 Indicator for liver health status identified A high-fat, high-sugar diet damages the liver in the long term. Scientists at the German Cancer Research Center (DKFZ) have now identified a characteristic change in the molecular signaling pathways of liver cells in mice that were exposed to such a diet for weeks. It fuels the division activity of hepatocytes and correlates with the risk of patients suffering liver failure after liver surgery.https://www.gesundheitsindustrie-bw.de/en/article/press-release/indicator-liver-health-status-identified
Press release - 17/01/2024 Immatics Announces Pricing of $175 Million Public Offering Immatics N.V. (NASDAQ: IMTX, “Immatics”), a clinical-stage biopharmaceutical company active in the discovery and development of T cell-redirecting cancer immunotherapies, announced today the pricing of an underwritten public offering of 15,925,000 ordinary shares at a public offering price of $11.00 per share. https://www.gesundheitsindustrie-bw.de/en/article/press-release/immatics-announces-pricing-175-dollar-million-public-offering
Press release - 17/01/2024 AI-based support system for skin cancer diagnostics explains its decisions Artificial intelligence (AI) can help dermatologists to detect skin cancer. However, many dermatologists distrust the algorithms' decisions, which they cannot comprehend. Scientists at the German Cancer Research Center have now developed an AI-based support system for skin cancer diagnostics that explains its decisions.https://www.gesundheitsindustrie-bw.de/en/article/press-release/ai-based-support-system-skin-cancer-diagnostics-explains-its-decisions
Press release - 15/01/2024 Maturation instead of cell death: Defective signalling pathways disrupt immune cell development Researchers at the Faculty of Medicine of the University of Freiburg discover key factor in the development of immune cells. New approaches for the treatment of ALPS.https://www.gesundheitsindustrie-bw.de/en/article/maturation-instead-cell-death-defective-signalling-pathways-disrupt-immune-cell-development
Event - 18/09/2024 - 20/09/2024 58th Annual Conference of the German Society for Biomedical Engineering (BMT 2024) Stuttgart, Kongress/Symposium https://www.gesundheitsindustrie-bw.de/en/event/58th-annual-conference-german-society-biomedical-engineering-bmt-2024
Health Data Futures project - 11/01/2024 Creating a network of trust In the three-nation project "Health Data Futures", stakeholders and experts from Germany, France and Switzerland have launched a series of patient-centred innovations. Using various future scenarios, the project partners may be able to come up with even more scenarios.https://www.gesundheitsindustrie-bw.de/en/article/news/creating-network-trust
Press release - 10/01/2024 MedTech Company KARL STORZ Acquires British AI Specialist Innersight Labs The family-owned MedTech company KARL STORZ announces the acquisition of the innovative software manufacturer Innersight Labs Ltd. (ISL) headquartered in London. In addition to state-of-the-art endoscopes, high-end medical devices, and integrated solutions for the operating room, KARL STORZ is also continuing to expand in innovative software solutions. https://www.gesundheitsindustrie-bw.de/en/article/press-release/medtech-company-karl-storz-acquires-british-ai-specialist-innersight-labs
Press release - 08/01/2024 Brain tumors in children: Cancer cells become less aggressive as they migrate within the tumor Certain brain tumors in small children contain cells that develop very similarly to normal brain cells and others that have already developed malignantly, depending on where they are located within the tumor. https://www.gesundheitsindustrie-bw.de/en/article/press-release/hirntumoren-bei-kindern-krebszellen-werden-auf-ihrer-wanderung-im-tumor-weniger-aggressiv
Press release - 05/01/2024 Prostate cancer: Newly-developed inhibitor shows massive potential More than 65,000 men fall ill with prostate cancer each year in Germany. Twelve thousand of them develop a treatment-resistant form which eventually ends in death. Now, a team of researchers from the Medical Faculty at the University of Freiburg has developed an active substance that might in future represent a new treatment option. https://www.gesundheitsindustrie-bw.de/en/article/press-release/prostate-cancer-newly-developed-inhibitor-shows-massive-potential
Press release - 05/01/2024 How memories are formed in the brain – a new role for the internal compass University of Tübingen neuroscientists discover new functions of head-direction cells suggesting they may contribute to episodic memory formation.https://www.gesundheitsindustrie-bw.de/en/article/press-release/how-memories-are-formed-brain-new-role-internal-compass
Press release - 04/01/2024 Key player in viral heart inflammation discovered Inflammation of the heart muscle, also known as myocarditis, is a serious consequence of a viral infection. This can impede the heart’s ability to pump blood in the long term. In a current study, researchers of the Faculty of Medicine of the University of Freiburg have discovered a new approach for treating myocarditis. https://www.gesundheitsindustrie-bw.de/en/article/press-release/key-player-viral-heart-inflammation-discovered
Press release - 03/01/2024 Reprogrammed fat cells support tumor growth Mutations of the tumor suppressor p53 not only have a growth-promoting effect on the cancer cells themselves, but also influence the cells in the tumor's microenvironment. Scientists at the Weizmann Institute in Israel and at the German Cancer Research Center (DKFZ) have now shown that p53-mutated mouse breast cancer cells reprogram fat cells.https://www.gesundheitsindustrie-bw.de/en/article/press-release/reprogrammed-fat-cells-support-tumor-growth
Event - 03/06/2024 - 06/06/2024 BIO International Convention 2024 San Diego, United States, Kongress/Symposium https://www.gesundheitsindustrie-bw.de/en/event/bio-international-convention-2024
Event - 27/05/2024 - 28/05/2024 Neuro4D Mainz, Conference https://www.gesundheitsindustrie-bw.de/en/event/neuro4d
Event - 18/06/2024 - 20/06/2024 MedtecLIVE 2024 Stuttgart, Messe https://www.gesundheitsindustrie-bw.de/en/event/medteclive-2024
Press release - 18/12/2023 Researchers discover novel antibiotic substance from the human nose For the first time, the active substance epifadin has been isolated at the University of Tübingen – Epifadin is produced by specific bacteria in the nose and on the skin of humans, has an antibiotic effect, and is the first example of a previously unknown antimicrobial compound class.https://www.gesundheitsindustrie-bw.de/en/article/press-release/researchers-discover-novel-antibiotic-substance-human-nose
All-enzyme hydrogels in action - 13/12/2023 Biocatalytic foams enable the sustainable synthesis of complex molecules Conventional chemical synthesis processes consume large amounts of energy and environmentally harmful solvents. Prof. Dr. Christof Niemeyer’s team at the Karlsruhe Institute of Technology has generated porous, solid foams from crosslinked enzymes that allow the production of high-quality compounds under significantly more environmentally friendly conditions. The novel biocatalysts are also extremely resistant and have a long shelf life.https://www.gesundheitsindustrie-bw.de/en/article/news/biocatalytic-foams-enable-sustainable-synthesis-complex-molecules
Press release - 11/12/2023 Heidelberg center for personalized medicine achieves the highest quality standards The German Cancer Society has certified the Center for Personalized Medicine (ZPM) at Heidelberg University Hospital. At the ZPM Heidelberg, patients with advanced and rare cancers and, in future, people with severe chronic inflammatory diseases will receive a molecular genetic analysis. The detailed information can open up new treatment options for those affected.https://www.gesundheitsindustrie-bw.de/en/article/press-release/zentrum-fuer-personalisierte-medizin-heidelberg-erfuellt-hoechste-qualitaetsstandards
Press release - 08/12/2023 Where does chronic pain come from? Professor Dr. Rohini Kuner from the Medical Faculty of Heidelberg University receives the Leibniz Prize of the German Research Foundation (DFG).https://www.gesundheitsindustrie-bw.de/en/article/press-release/woher-kommen-chronische-schmerzen
Computer-assisted genome mining - 04/12/2023 Natural product genomics opens up new avenues in the search for antibiotics Antibiotic-resistant pathogens are increasingly endangering our health. Since most of the drugs currently in use are based on secondary metabolites produced by bacteria or fungi, the research group of Prof. Dr. Nadine Ziemert in Tübingen is developing bioinformatic tools to specifically search the genome of these organisms for previously unknown antimicrobial agents.https://www.gesundheitsindustrie-bw.de/en/article/news/natural-product-genomics-opens-new-avenues-search-antibiotics
Press release - 30/11/2023 Taking antibiotics back in time University of Tübingen researchers reverse the evolution of a class of antibiotics to gain insights for the development of new drugs.https://www.gesundheitsindustrie-bw.de/en/article/press-release/taking-antibiotics-back-time
Press release - 29/11/2023 Tracing the Evolution of the Cerebellum Heidelberg scientists unveil genetic programmes controlling the development of cellular diversity in the cerebellum of humans and other mammals. The research results have now been published in the journal Nature.https://www.gesundheitsindustrie-bw.de/en/article/press-release/tracing-evolution-cerebellum
Press release - 29/11/2023 EU funds research into causes and new therapies for multiple sclerosis The progression of multiple sclerosis (MS) can usually be slowed down with medication, but a cure is currently not possible. It is now established that Epstein-Barr viruses are involved in the development of MS. However, it is not known how the pathogens trigger the disease. The European Union is now funding the international research consortium BEHIND-MS as part of its HORIZON Europe program.https://www.gesundheitsindustrie-bw.de/en/article/press-release/eu-foerdert-forschung-zu-ursachen-und-neuen-therapien-der-multiplen-sklerose
Press release - 15/11/2023 Nanoparticles for optimized cancer therapy Pancreatic cancer is one of the deadliest types of cancers in humans. Chemotherapies attack not only the tumor cells but also healthy cells throughout the body. Innovative nanoparticles could be a new approach to treat cancer more precisely. The approach was developed by a research team from the Max Planck Institute (MPI) for Multidisciplinary Sciences, the University Medical Center Göttingen (UMG), and the Karlsruhe Institute of Technology.https://www.gesundheitsindustrie-bw.de/en/article/press-release/nanopartikel-fuer-optimierte-krebstherapie
Augmented reality for visual orientation - 15/11/2023 Fall prevention with the help of balance-enhancing AR glasses As we age, our eyesight deteriorates and we have increasing difficulties with orientation. This can lead to balance problems and fatal falls. A team led by Dr. Lorenz Assländer from the University of Konstanz is currently developing a prototype of augmented reality (AR) glasses that use superimposed patterns to facilitate visual orientation in space, thereby helping to improve balance control and prevent falls.https://www.gesundheitsindustrie-bw.de/en/article/news/fall-prevention-help-balance-enhancing-ar-glasses
Press release - 10/11/2023 Therapy resistance in multiple myeloma: molecular analyses of individual cancer cells reveal new mechanisms All cancer cells - even those within the same tumor - differ from each other and change over the course of a cancer disease. Scientists at Heidelberg University Hospital, the Medical Faculty in Heidelberg and the German Cancer Research Center discovered molecular changes in multiple myeloma that help individual cancer cells to survive therapy.https://www.gesundheitsindustrie-bw.de/en/article/press-release/therapy-resistance-multiple-myeloma-molecular-analyses-individual-cancer-cells-reveal-new-mechanisms
Nanoparticles as drug carriers - 09/11/2023 Inhalation of nanocarriers for antibiotics against resistant tuberculosis pathogens Around ten million people worldwide still contract tuberculosis every year. With an estimated 1.4 million deaths a year, tuberculosis was the world’s deadliest infectious disease until COVID-19. The high mortality rate is down to the sophisticated biology of the pathogen Mycobacterium tuberculosis. A team of researchers from the KIT and the Research Centre Borstel (FZB) has developed a method that aims to outsmart the bacterium once and for all.https://www.gesundheitsindustrie-bw.de/en/article/news/inhalation-nanocarriers-antibiotics-against-resistant-tuberculosis-pathogens
Press release - 06/11/2023 Improving the efficacy of cancer immunotherapy with modified CAR-T cells CAR-T cell therapy is a last hope for many patients with blood, bone marrow or lymph gland cancer when other treatments are unsuccessful. A limiting factor of this very effective and safe therapy is that the cells used in the process quickly reach a state of exhaustion. Researchers at the University of Freiburg have now been able to prevent this exhaustion and thus significantly improve the effect of the therapy in a preclinical animal model.https://www.gesundheitsindustrie-bw.de/en/article/press-release/improving-efficacy-cancer-immunotherapy-modified-car-t-cells
Press release - 30/10/2023 New research group: construction of tissue in laboratory An interdisciplinary research group combining mechanical engineering and biotechnology has taken up its work at the Institute for Molecular Systems Engineering and Advanced Materials (IMSEAM) of Heidelberg University. The team under the direction of Dr Kai Melde will pursue an innovative approach to biofabrication – 3D cell culture using ultrasound. Tools are being developed that can be used as an alternative to or enhancement for 3D printing. https://www.gesundheitsindustrie-bw.de/en/article/press-release/neue-forschungsgruppe-konstruktion-von-gewebe-im-labor
High-resolution microscopy technology bypassing the diffraction limit - 26/10/2023 From micro- to nanoscope It has long been impossible to distinguish objects closer than 200 nanometres using light microscopes. However, novel devices developed by a company called abberior Instruments GmbH, which use technology developed by Nobel Prize winner Prof. Dr. Stefan Hell and his teams in Heidelberg and Göttingen, are now able to bypass this resolution limit and provide detailed insights into living cells in the lower nanometre range.https://www.gesundheitsindustrie-bw.de/en/article/news/micro-nanoscope
Press release - 26/10/2023 Innovative research aims to improve wound healing and cancer therapy Jun.-Prof. Dr. Priscilla Briquez, junior professor at the Department of General and Visceral Surgery at the Freiburg University Medical Center and member of the Medical Faculty at the University of Freiburg, has received a European Research Council (ERC) Starting Grant from the European Commission. Her DRESSCODE project will receive a total of 1.5 million euros funding for five years.https://www.gesundheitsindustrie-bw.de/en/article/press-release/innovative-forschung-soll-wundheilung-und-krebstherapie-verbessern
Press release - 25/10/2023 Epigenetically acting drugs could support cancer immunotherapy Epigenetically active drugs enable the cell to read parts of the genome that were previously blocked and inaccessible. This leads to the formation of new mRNA transcripts and also new proteins, as scientists from the German Cancer Research Center and the University Hospital Tübingen have now published. These "therapy-induced epitopes" could help the immune system recognize cancer cells.https://www.gesundheitsindustrie-bw.de/en/article/press-release/epigenetically-acting-drugs-could-support-cancer-immunotherapy
Press release - 25/10/2023 Epigenetically acting drugs could support cancer immunotherapy Epigenetically active drugs enable the cell to read parts of the genome that were previously blocked and inaccessible. This leads to the formation of new mRNA transcripts and also new proteins, as scientists from the German Cancer Research Center and the University Hospital Tübingen have now published. These "therapy-induced epitopes" could help the immune system recognize cancer cells.https://www.gesundheitsindustrie-bw.de/en/article/press-release/epigenetisch-wirkende-medikamente-koennten-krebs-immuntherapie-unterstuetzen
Press release - 20/10/2023 Why tuberculosis bacteria form long chains A researcher team from Ecole Polytechnique Federal de Lausanne led by Dr. Vivek Thacker now group leader at the Department of Infectious Diseases at Heidelberg University Hospital have studied why tuberculosis bacteria form long strands and how this affects their infectivity. Their findings could lead to new therapies and have now been published in the journal Cell.https://www.gesundheitsindustrie-bw.de/en/article/press-release/why-tuberculosis-bacteria-form-long-chains
Press release - 18/10/2023 SARS-CoV-2: Alert immune system in the respiratory tract protects children from severe courses of the disease Why are severe courses of SARS-CoV-2 infection less common in children and adolescents than in adults? Scientists at the German Cancer Research Center (Deutsches Krebsforschungszentrum, DKFZ) have now discovered that the immune system in the upper respiratory tract is much more alert and active in children before infection than in adults and is therefore better equipped to fight the virus.https://www.gesundheitsindustrie-bw.de/en/article/press-release/sars-cov-2-aktiveres-immunsystem-den-atemwegen-schuetzt-kinder-vor-schweren-verlaeufen
Press release - 17/10/2023 BioCopy and YUMAB announce partnership for development of innovative safeTY-engager® platform The development of highly specific T-cell engagers directed against pHLA tumor targets will be quick and easy. BioCopy's innovative pHLA screening technology characterizes drug candidates in great depth for their specific binding against the desired pHLA tumor target. YUMAB develops highly specific antibodies with their advanced antibody technologies.https://www.gesundheitsindustrie-bw.de/en/article/press-release/biocopy-und-yumab-verkuenden-partnerschaft-fuer-entwicklung-innovativer-safety-engager-r-plattform
Press release - 11/10/2023 The new Center for Bionic Intelligence Tübingen Stuttgart The new Center for Bionic Intelligence Tübingen Stuttgart aims to optimize the interaction between humans and technical systems in a fundamentally new way. Scientists from the Universities of Stuttgart and Tübingen, the Max Planck Institute for Intelligent Systems and the Max Planck Institute for Biological Cybernetics are conducting research on intelligent bionic systems that will aid understanding and treatment of certain diseases of the CNS.https://www.gesundheitsindustrie-bw.de/en/article/press-release/zentrum-fuer-bionic-intelligence-tuebingen-stuttgart-gegruendet
Dossier - 11/10/2023 The quantum revolution in the healthcare industry From ultra-fast quantum computers to highly sensitive sensors - quantum technologies could take medicine a giant step forward. Possible areas of application range from drug development and early cancer detection to reading brain waves to control prostheses or exoskeletons. The German state of Baden-Württemberg plays a key role in the development of sensors in particular.https://www.gesundheitsindustrie-bw.de/en/article/dossier/The-quantum-revolution-in-the-healthcare-industry
Press release - 04/10/2023 Therapeutic option for tumor patients with the rare DNAJB1-PRKACA gene fusion A phase I clinical trial is now starting at Tuebingen University Hospital in the Clinical Collaboration Unit (CCU) Translational Immunology, in collaboration with the Department of Internal Medicine I, which is investigating the therapeutic cancer peptide vaccine Fusion-VAC-XS15 in combination with immune checkpoint blockade by atezolizumab (Tecentriq®). https://www.gesundheitsindustrie-bw.de/en/article/press-release/therapeutic-option-tumor-patients-rare-dnajb1-prkaca-gene-fusion
Press release - 02/10/2023 Distributed artificial intelligence to improve patient care in the operating room A research team of scientists from the Fraunhofer IPA, the Bosch Digital Innovation Hub at Bosch Health Campus and the Institute of Image-Guided Surgery (IHU) of Strasbourg has jointly launched the DAIOR project. Within the framework of the project, the project partners are working on realizing the operating room of the future with help of artificial intelligence and robot assisted telemedicine. https://www.gesundheitsindustrie-bw.de/en/article/press-release/distributed-artificial-intelligence-improve-patient-care-operating-room
Help with osteoarthritis of the knee - 27/09/2023 Individualised knee-joint cartilage: artificial tissue that fits Knee joints are subject to considerable stress throughout our lives. The natural shock absorber cartilage wears out over a lifetime, so many people develop knee osteoarthritis. Treatment is available in the form of artificial cartilage. This "off-the-shelf" tissue often does not grow well. Researchers are developing an individualised cartilage replacement made from biomaterial that is produced by 3D printing based on MRI images.https://www.gesundheitsindustrie-bw.de/en/article/news/individualised-knee-joint-cartilage-artificial-tissue-fits
Press release - 21/09/2023 Mutation-specific peptide vaccine against midline gliomas used in patients for the first time Tumor vaccines can help the body fight cancer. These vaccines alert the patient's immune system to proteins that are harbouring cancer-typical alterations. Physicians and cancer researchers from Heidelberg and Mannheim have now treated adult patients with advanced midline gliomas, difficult-to-treat brain tumors, with a peptide vaccine for the first time.https://www.gesundheitsindustrie-bw.de/en/article/press-release/mutation-specific-peptide-vaccine-against-midline-gliomas-used-patients-first-time
Press release - 19/09/2023 Better distinguish chronic inflammation and cancer of the pancreas Current diagnostic methods do not always reliably distinguish between chronic inflammation of the pancreas and pancreatic cancer. About one third of all diagnoses are inconclusive. Scientists from the German Cancer Research (DKFZ) and from Heidelberg University Hospital (UKHD) therefore searched for molecular markers that could specify this diagnosis.https://www.gesundheitsindustrie-bw.de/en/article/press-release/chronische-entzuendung-und-krebs-der-bauchspeicheldruese-praeziser-unterscheiden
Project SMARTGAIT - 13/09/2023 Safe and cost-effective analysis of neurological gait disorders with AI Stroke, Parkinson's disease and multiple sclerosis often resulting in gait disorders in those affected. Gait analyses play a crucial role in the successful evaluation and therapy of such disorders. Current measurement methods are costly and time-consuming. The SMARTGAIT project is therefore developing an innovative AI-based system aimed at performing meaningful gait analyses with the help of simple smartphone video recordings.https://www.gesundheitsindustrie-bw.de/en/article/news/safe-and-cost-effective-analysis-neurological-gait-disorders-ai
Sustainability report - 31/08/2023 ReKlimaMed: how effective is the German healthcare sector when it comes to sustainability? Hospitals, care facilities and the healthcare industry, together with laboratories, private practices and pharmacies, ensure our medical care, but in so doing they produce enormous amounts of greenhouse gases and consume many resources. The ReKlimaMed report prepared by the viamedica foundation presents an inventory of current sustainable activities, and provides stakeholders with information and recommendations for action.https://www.gesundheitsindustrie-bw.de/en/article/news/reklimamed-how-effective-german-healthcare-sector-when-it-comes-sustainability
Press release - 28/08/2023 Innovative computational approach helps design proteins for cancer treatment The computational design of new proteins for biomedical or other applications involves long computing times on powerful servers. A joint team of researchers from the Max Planck Institute for Biology Tübingen and the University Hospital Tübingen has now developed and tested a new computational method to greatly speed up the necessary energy calculations. Their framework allows for a precise and efficient design of functional proteins.https://www.gesundheitsindustrie-bw.de/en/article/press-release/innovative-computational-approach-helps-design-proteins-cancer-treatment
DNA nanotechnology - 25/08/2023 Artificial cytoskeleton made of DNA for synthetic cells The physicists Prof. Dr. Kerstin Göpfrich and Prof. Dr. Laura Na Liu want to understand life from the bottom up. They intend to do this by constructing an artificial cell. However, rather than natural protein building blocks, they are using 3D-DNA structures as construction material. The first step involved creating an artificial cell skeleton that dynamically assembles and disassembles like the biological model and can transport vesicles.https://www.gesundheitsindustrie-bw.de/en/article/news/artificial-cytoskeleton-made-dna-synthetic-cells
Press release - 18/08/2023 TÜV SÜD gets UK Approved Body designation TÜV SÜD has received approval as a UK Approved Body (UKAB) for medical devices. With this approval, medical device manufacturers can implement UKCA certification for the UK market and CE certification for the European market in a time- and cost-efficient manner with TÜV SÜD.https://www.gesundheitsindustrie-bw.de/en/article/press-release/tuev-sued-gets-uk-approved-body-designation
Press release - 10/08/2023 Computer-aided cell analysis for faster diagnosis of blood diseases Scientists from the German Cancer Research Center (DKFZ) and the Cambridge Stem Cell Institute have developed an AI system that recognizes and characterizes white and red blood cells in microscopic images of blood samples. The algorithm can help physicians diagnose blood disorders and is available as an open source method for research purposes.https://www.gesundheitsindustrie-bw.de/en/article/press-release/computergestuetzte-zellanalyse-fuer-die-schnellere-diagnose-von-blutkrankheiten
Press release - 07/08/2023 Vegan trend in Europe: In Germany, milk substitutes from plants are most popular alternative Germany has the most active market, Southern Europe wants more variety, and people in Poland find dairy substitutes too expensive, according to a recent study by the University of Hohenheim.https://www.gesundheitsindustrie-bw.de/en/article/press-release/vegan-trend-europe-germany-milk-substitutes-plants-are-most-popular-alternative
Overview Press release was not found https://www.gesundheitsindustrie-bw.de/en/article/press-release/press-release-was-not-found
Overview Dossier was not found https://www.gesundheitsindustrie-bw.de/en/article/dossier/dossier-was-not-found
Overview Article was not found https://www.gesundheitsindustrie-bw.de/en/article/news/article-was-not-found
Project BlindZero - 03/08/2023 Hope for patients with eye diseases: human cornea from 3D printers Thousands of cornea transplants are performed every year. However, donors are rare and the procedure is not always without complications. Researchers at the University of Heidelberg are developing an innovative technique in the project BlindZero. It involves ‘printing’ human corneas directly onto patients’ eyes using 3D bioprinting. The reprogrammed genetically engineered cells used for this purpose are not expected to cause a rejection reaction.https://www.gesundheitsindustrie-bw.de/en/article/news/hope-patients-eye-diseases-human-cornea-3d-printers
Press release - 02/08/2023 Freiburg research team casts light on signal-dependent formation of mitochondria Known as the power plant of the cell, mitochondria are essential to human metabolism. Human mitochondria consist of 1,300 different proteins and two fatty biomembranes. The vast majority of mitochondrial proteins are produced with a cleavable transport signal and have to be actively transported into the mitochondria. https://www.gesundheitsindustrie-bw.de/en/article/press-release/freiburger-forschungsteam-klaert-signalabhaengige-bildung-von-mitochondrien-auf
NeuroQ project - 26/07/2023 Quantum sensors for exoskeletons: can quantum physics beat paralysis? Could people suddenly be able to move again decades after being paralysed? State-of-the-art quantum sensors integrated in exoskeletons could make this possible. Technology being developed as part of the BMBF-funded NeuroQ beacon project by researchers from organisations including the Fraunhofer IAF, the Charité in Berlin and the University of Stuttgart might achieve even more: besides facilitating movement, it could also help cure paralysis.https://www.gesundheitsindustrie-bw.de/en/article/news/quantum-sensors-exoskeletons-can-quantum-physics-beat-paralysis
Press release - 20/07/2023 Animal testing under REACH: bringing numbers into the debate So far, 4.2 million animal tests under the REACH chemical regulation: A study from Konstanz and Baltimore quantifies the number of animals that died for the hazard assessment of chemicals in the chemical industry.https://www.gesundheitsindustrie-bw.de/en/article/press-release/tierversuche-durch-reach-zahlen-die-debatte-bringen
Press release - 20/07/2023 Anal Cancer Screening: New Microbiome-Associated Biomarkers Could Improve Prevention A new study published in Nature Medicine, July 2023 has identified two novel markers for screening high-grade squamous intraepithelial lesions (HSIL), a precursor to anal cancer, from the anal microbiome of people with HIV (PWH). PWH are at a significantly higher risk of developing anal cancer. Current screening methods, such as anal cytology, have low specificity for detecting HSIL, which hinders the prevention of anal cancer.https://www.gesundheitsindustrie-bw.de/en/article/press-release/anal-cancer-screening-new-microbiome-associated-biomarkers-could-improve-prevention
Tumour organoids facilitate drug discovery - 20/07/2023 Drug screening for children with cancer using patient-specific miniature tumours Standard drugs often don’t work in children and adolescents with recurrent cancer. Researchers from the Hopp Children's Tumour Centre (KITZ) and the German Cancer Research Center (DKFZ) in Heidelberg have been looking to open up new therapy options for those affected, and have cultivated individual miniature tumours from biopsy samples to test the effectiveness of a variety of drugs within a few weeks.https://www.gesundheitsindustrie-bw.de/en/article/news/drug-screening-children-cancer-using-patient-specific-miniature-tumours
Press release - 18/07/2023 National Research Center for cutting-edge AI research in Tübingen celebrates inception On Tuesday, July 18, 2023, the Tübingen AI Center held a symposium to celebrate its permanent establishment as a national AI center. Since July 1, 2022, it has received 20 million euros a year in funding from the federal government and the state. https://www.gesundheitsindustrie-bw.de/en/article/press-release/nationales-forschungszentrum-fuer-ki-spitzenforschung-tuebingen-feiert-seine-gruendung
Press release - 13/07/2023 Intelligent rubber materials Wearable medical devices, such as soft exoskeletons that provide support for stroke patients or controlled drug delivery patches, have to be made of materials that can adapt intelligently and autonomously to the wearer's movements and to changing environmental conditions. These are the type of autonomously switchable polymer materials that have recently been developed by researchers at the University of Stuttgart and the University of…https://www.gesundheitsindustrie-bw.de/en/article/press-release/intelligent-rubber-materials
Press release - 12/07/2023 Mast cells as a sensor: Enigmatic immune cells help to avoid harmful allergens The function of mast cells, which are part of the immune system, is still a mystery. Scientists at the German Cancer Research Center (DKFZ) have now shown in mice: mast cells function as a sensor that signals the animals to avoid antigens, including harmful allergens, and thereby protect themselves from health-threatening inflammatory reactions. The findings were published in the journal Nature.https://www.gesundheitsindustrie-bw.de/en/article/press-release/mastzellen-als-sensor-raetselhafte-immunzellen-helfen-schaedliche-allergene-zu-vermeiden
Expert interview - 05/07/2023 Every tenth of a degree matters when it comes to mitigating the consequences of global warming: sustainability measures in the laboratory The life sciences sector consumes huge quantities of energy and resources. This needs to change and we have to think differently. But how and where can sustainability measures be sensibly applied in the laboratory without compromising the quality of research results? Dr. Kerstin Hermuth-Kleinschmidt, owner of NIUB-Nachhaltigkeitsberatung, a company from Freiburg that focuses on sustainability in life sciences, tells BIOPRO how this can be done.https://www.gesundheitsindustrie-bw.de/en/article/news/every-tenth-degree-matters-when-it-comes-mitigating-consequences-global-warming-sustainability-measures-laboratory
Expert interview - 28/06/2023 Money isn't all that is needed – knowledge and networking can also help start-ups move forward Dr. Rolf Neuhaus is one of the driving forces behind PALATINA Business Angels Rhein-Neckar e.V., a business angels association in the Rhine-Neckar metropolitan region. In an interview with BIOPRO, Neuhaus describes the association’s activities and explains where there is still catching up to be done in terms of start-up support in Baden-Württemberg.https://www.gesundheitsindustrie-bw.de/en/article/news/money-isnt-all-needed-knowledge-and-networking-can-also-help-start-ups-move-forward
Press release - 23/06/2023 The molecular control centre of our protein factories Researchers from Konstanz and Zurich have deciphered a biochemical mechanism that ensures that newly formed proteins are processed correctly when they leave the cell's own protein factories. This solves a decade-old puzzle in protein sorting.https://www.gesundheitsindustrie-bw.de/en/article/press-release/molecular-control-centre-our-protein-factories
Predicting the success of cancer treatment - 20/06/2023 Focusing on gut microbiome for CAR T-cell therapy Cancer immunotherapies use the body's own defences to fight tumour cells. An international consortium of researchers from Germany and the USA led by the DKFZ in Heidelberg has demonstrated that the effectiveness of CAR T-cell therapies greatly depends on the composition of the gut microbiome. The researchers have also developed a model for predicting the long-term response to the treatment.https://www.gesundheitsindustrie-bw.de/en/article/news/focusing-gut-microbiome-car-t-cell-therapy
Press release - 20/06/2023 Pangolin the inspiration for medical robot Scientists at the Max Planck Institute for Intelligent Systems in Stuttgart have developed a magnetically controlled soft medical robot with a unique, flexible structure inspired by the body of a pangolin. The robot is freely movable despite built-in hard metal components. Thus, depending on the magnetic field, it can adapt its shape to be able to move and can emit heat when needed.https://www.gesundheitsindustrie-bw.de/en/article/press-release/pangolin-inspiration-medical-robot
Press release - 20/06/2023 CureVac Doses First Patient in Phase 1 Study of Cancer Vaccine Candidate for Surgically Resected Glioblastoma CureVac N.V. today announced that it has dosed the first patient with its investigational cancer vaccine CVGBM in a Phase 1 study. CVGBM is based on CureVac’s proprietary second-generation mRNA backbone and features a single mRNA, encoding eight epitopes derived from known tumor-associated antigens with demonstrated relevance in glioblastoma. A first data readout is expected in the second half of 2024.https://www.gesundheitsindustrie-bw.de/en/article/press-release/curevac-doses-first-patient-phase-1-study-cancer-vaccine-candidate-surgically-resected-glioblastoma
Press release - 20/06/2023 Tuberculosis Therapy: Smallest Particles Will Deliver the Drug to the Lungs in Future KIT and Research Center Borstel Present Nanoparticles with a High Antibiotic Concentration for Inhalation – Nanocarriers of Antibiotics Can Reduce Resistances and Enhance Compatibility.https://www.gesundheitsindustrie-bw.de/en/article/press-release/tuberculosis-therapy-smallest-particles-will-deliver-drug-lungs-future
Press release - 16/06/2023 What determines whether breast cancer cells can form metastases? In most cancers, it is not the growth of the primary tumor that determines the prognosis for the patient, but whether it will spread and form metastases. This process is very complex. There are often years between the development of the cancer and the aggressive growth of the metastases. Scientists from the DKFZ, the HI-STEM, the Ruhr University Bochum, Helmholtz Munich and ETH Zurich have studied and identified metastasis growth in breast cancerhttps://www.gesundheitsindustrie-bw.de/en/article/press-release/what-determines-whether-breast-cancer-cells-can-form-metastases
Press release - 13/06/2023 AutoProNano – international cooperation for in vitro and in vivo diagnostics The AutoProNano German/French collaborative project involves developing a process for the automated production of nanoparticles for in vitro and in vivo diagnostics. The project is being launched within the smart analytics cooperation network. This international initiative has been funded by the Central Innovation Programme for SMEs (ZIM) of the German Federal Ministry for Economic Affairs and Climate Action (BMWK) since May 2020.https://www.gesundheitsindustrie-bw.de/en/article/press-release/autopronano-international-cooperation-vitro-and-vivo-diagnostics
Press release - 05/06/2023 New findings about human metabolic processes Researchers at the Faculty of Medicine at the University of Freiburg have gained significant new insights into metabolic processes in the kidney. The scientists from the Institute of Genetic Epidemiology at the Medical Center - University of Freiburg measured tiny molecules, so-called metabolites, which occur in blood and urine and reflect our metabolism, in samples from more than 5,000 study participants.https://www.gesundheitsindustrie-bw.de/en/article/press-release/new-findings-about-human-metabolic-processes
Reduced immunosuppression possible in transplantations - 05/06/2023 Modified immune cells produce donor-specific tolerance Traditionally, transplant recipients have had to take immunosuppressive medication for life to prevent organ rejection. However, there are considerable side effects involved. Using modified immune cells (MICs), TolerogenixX GmbH from Heidelberg has now managed to generate donor-specific tolerance in recipients of living kidney transplants without suppressing the overall immune system.https://www.gesundheitsindustrie-bw.de/en/article/news/modified-immune-cells-produce-donor-specific-tolerance
Detecting drug resistance of tumour cells - 25/05/2023 AI-assisted diagnostics declares war on lung cancer Lung cancer is one of the most common cancers and has a particularly high mortality rate. A significant challenge in treating this disease lies in the resistance of lung tumours to conventional drug therapies, rendering chemotherapy ineffective. There is hope on the horizon as a team of experts from Baden-Württemberg has joined forces to develop an innovative AI-supported test procedure that paves the way for individualised therapy approaches.https://www.gesundheitsindustrie-bw.de/en/article/news/ai-assisted-diagnostics-declares-war-lung-cancer